
|Articles|December 1, 2006
Success with pemphigus vulgaris
Boston - A combination of Rituxan (rituximab, Genentech) and intravenous immune globulin (IVIG) can be effective in patients with severe refractory pemphigus vulgaris, a study in the New England Journal of Medicine reports.
Advertisement
Boston - A combination of Rituxan (rituximab, Genentech) and intravenous immune globulin (IVIG) can be effective in patients with severe refractory pemphigus vulgaris, a study in the New England Journal of Medicine reports.
Nine of 11 patients with severe disease had remissions lasting up to three years when treated with a combination of Rituxan and IVIG, according to
Two additional patients had complete resolution of lesions after additional infusions of Rituxan alone.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clinicians Weigh Topical Sequencing and Escalation in Complex Atopic Dermatitis Cases
2
CSU With Biochemical C1 Inhibitor Deficiency: Case Report Raises Diagnostic Questions
3
Common Mistakes in Managing Hair Loss and Pigmentary Disorders
4
Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial
5











